About Rickway

The company was founded in 2016 with a registered capital of RMB 16153846. The shareholders of the company are: Hainan ruikewei Pharmaceutical Co., Ltd. holds 60%, and Nanjing Hairong Pharmaceutical Technology Co., Ltd. holds 40%. An innovative pharmaceutical platform enterprise committed to drug R & D and industrialization, mainly focusing on the drugs used in core cardiology examination. Based on the principle of "drug marketing license holder" system and considering the characteristics of long cycle and high risk in the process of drug research and development to marketing, the company is specially established to accelerate the industrialization of drug research and development and achieve the purpose of risk sharing and benefit sharing.

发展历程

  • 2016.6.14
    公司成立,注册名称:南京海美生物医药有限公司,注册资金400万元
  • 2021.5.19
    公司更名为:南京瑞克卫生物医药有限公司,注册资金1615.3846万元
  • 2021.10.29
    取得药品生产许可证
  • 2021.10.30
    瑞加诺生注射液获得上市许可
瑞克卫质量投诉电话:13303115272 邮箱:rm@recovery-medica.com